Caliper Sells Two Product Lines to Biotage | GenomeWeb

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Continuing its strategy to divest non-core parts of its business, Caliper Life Sciences today announced it has reached an agreement to sell its RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5 million in cash.

Biotage also assumes liabilities of about $500,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.